Background: The epirubicin with cisplatin and infusional 5-fluorouracil (5-FU) (ECisF) regimen was found to be highly active in the treatment of metastatic breast cancer and as neoadjuvant therapy. The UK TRAFIC (trial of adjuvant 5-FU infusional chemotherapy) trial (CRUK/95/007) compared this schedule with 5-FU, epirubicin and cyclophosphamide (FEC60) as adjuvant therapy in patients with early breast cancer. Results: All randomised patients were included in the intent-to-treat population. With a median follow-up of 112 months, there was no significant difference in RFI between the treatment groups [hazard ratio 0.84 (95% confidence interval 0.60-1.19); P = 0.33]. Toxic effects were more frequent in patients allocated to ECisF.
introduction Survival for women with early breast cancer over the past 30 years has improved with the use of adjuvant chemotherapy. In 1995, when TRAFIC (trial of adjuvant 5-FU infusional chemotherapy) was developed, there was no established role for the use of taxanes in the adjuvant treatment of early breast cancer; capecitabine was not yet available as an alternative to conventional 5-fluorouracil (5-FU) and other novel approaches were being explored [1] . These included a combination of continuous infusional 5-FU with conventional cisplatin and epirubicin (infusional ECisF), which had been shown to be very active against advanced breast cancer. Jones et al. [2] enrolled 43 patients with metastatic (n = 29) or locally advanced/ inflammatory (n = 14) breast cancer in a phase II trial of eight courses of ECisF. The overall response rate was 84% [95% confidence interval (CI) 76% to 96%], with a complete response rate of 24% (95% CI 9% to 40%) in patients with metastatic disease and 36% (95% CI 11% to 61%) in patients with locally advanced disease.
Smith et al. [3] treated 50 patients with large operable breast cancer with eight courses of ECisF; median tumour diameter was 6 cm (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Forty-nine patients achieved an overall response (98%; 95% CI 94% to 100%), including 33 complete clinical remissions (66%; 95% CI 53% to 79%) and only 3 patients (6%) required mastectomy. The infusional ECisF schedule had been selected empirically on the basis of its efficacy in the treatment of gastro-oesophageal carcinoma where it had shown a high response rate [4] . On the basis of above advanced breast cancer results and neoadjuvant chemotherapy trials, two phase III multicentre trials were instigated. The first was a neoadjuvant trial of preoperative infusional chemotherapy (TOPIC) compared with conventional chemotherapy [5] , and the second was TRAFIC, the results of which are presented here with a 9.5-year median follow-up. TRAFIC was powered to detect a large [40%, i.e. a hazard ratio (HR) of 0.6] relative reduction in the relapse rate attributable to infusional ECisF because a large reduction was felt to be necessary to compensate for the added side-effects and inconvenience of this regimen.
methods patients
This multicentre, phase III randomised controlled trial was undertaken in 11 centres in the UK (see Appendix). Patients eligible for the trial were women with histologically proven invasive breast cancer, node positive or node negative, with risk characteristics considered by the clinician at that time to justify offering adjuvant chemotherapy. Patients needed to have normal haematological, hepatic and renal function. Other staging investigations (e.g. isotopic bone scan, computed tomography scan) were only carried out where clinically indicated to exclude suspicion of metastatic disease. Patients were assessed as being competent to learn to look after their infusional pumps.
Patients were excluded if they had a previous malignancy (excluding carcinoma in situ of cervix or basal cell carcinoma), had uncontrolled angina pectoris, cardiac failure, clinically significant uncontrolled cardiac arrhythmias or any other serious uncontrolled medical condition.
TRAFIC was approved by the local ethics committee of each collaborating institution (pre-instigation of Multi-Research Ethics Committee CCR number 1157 at The Royal Marsden NHS Foundation Trust). All enrolled patients provided informed consent. ICR Clinical Trials and Statistics Unit (ICR-CTSU) at The Institute of Cancer Research, Sutton, Surrey, UK, had responsibility for trial coordination and randomisation. The Trial Management Group was responsible for the day to day running of the trial. Data were collated at regular intervals at ICR-CTSU where all interim and final analyses were done. Central statistical monitoring was carried out by ICR-CTSU.
randomisation
Patients were randomised in a 1 : 1 ratio to the experimental ECisF regimen or to control 5-FU, epirubicin and cyclophosphamide (FEC60).
Independent randomisation was by telephone to the ICR-CTSU and computer-generated permuted blocks were used. Stratification was by centre and nodal status (0-3 or 4+). The trial was open-label. bolus day 1). Both treatments were delivered 3 weekly for six cycles. In those patients allocated to receive ECisF, carboplatin could be substituted for cisplatin in the event of renal toxicity, peripheral neuropathy or persistent emesis. The carboplatin dose was calculated according to renal function with an area under the curve of 5 mg/ml/min. It was recommended that patients receiving infusional ECisF were started on oral low-dose warfarin 1 mg daily while the Hickman line remained in situ.
If white blood cell count was <3.0 · 10 9 /l or platelets <100 · 10 9 /l, the recommendation was for treatment with epirubicin and cisplatin to be delayed by 1 week (5-FU was continued) but given at full dose. If treatment was delayed by 2 weeks, then a dose reduction of 25% for all drugs was advised. If a delay of >2 weeks occurred, then a 50% reduction of all drug dosages was advised. Standard treatment of patients with any grade of plantar-palmar erythema (PPE) was recommended to be pyridoxine 50-150 mg orally three times daily throughout treatment. For grade 3 or more mucositis or PPE, 5-FU was interrupted for 1-2 weeks until healing and then recommenced with a 25% dose reduction of 5-FU, but with full dose for the other drugs. Granulocyte colony-stimulating factor was not used during this trial. Adverse events were assessed after every chemotherapy cycle (according to Common Terminology Criteria for Adverse Events v3) and performance status assessed according to the World Health Organization and all patients were followed up every 3 months for 2 years after treatment, 6 months for 5 years and annually thereafter.
It was recommended that adjuvant radiotherapy was administered if clinically appropriate and according to local practice and that it should conform to a standard dose and fraction schedule (unless the patient participated in a trial of breast radiotherapy fractionation).
All patients with hormone-sensitive breast cancer were offered adjuvant tamoxifen 20 mg orally daily. The timing of commencement was according to local practice but the recommendation was to continue for 5 years.
Selected centres invited patients to participate in a questionnaire-based quality of life substudy (European Organisation for Research and Treatment of Cancer QLC-C30), which was given to patients when they attended clinic. Patients were asked to complete the questionnaire at baseline, after the third and sixth course of chemotherapy and on completion of trial-related treatment. During the period in which this trial was carried out, quality-of-life studies were not routine part of research studies, and overall compliance was poor.
statistical analysis
The primary end point was relapse-free interval (RFI), the time from randomisation to the first local or distant recurrence. If neither of these events occurred, the patient's follow-up was censored at the time of last follow-up. The secondary end points were overall survival and toxicity. Survival was measured from the date of randomisation.
The proportion of patients local and distant relapse free at 5 years was anticipated to be 30% with conventional FEC60, and an improvement to 50% with infusional ECisF was sought. Accrual was planned to include at least 400 patients to allow for the detection of an absolute improvement in RFI by 5 years of 20% with a power of >95% and a two-sided significance level of 5%. This is equivalent to a 40% reduction in the instantaneous relapse rate, i.e. a HR of 0.6. This level was considered sufficient to offset the additional toxicity and inconvenience anticipated with infusional ECisF. The principal analysis included all patients as randomised on an intentionto-treat basis.
The patient characteristics of the two treatment groups were compared by means of the chi-squared test with Yates correction or Fisher's exact test for categorical data or the Mann-Whitney U test for quantitative or ordinal data. Survival curves were constructed by the Kaplan-Meier method and compared by means of the log-rank test; HRs were calculated assuming proportional hazards (using Cox regression). HRs <1.0 being in favour of infusional ECisF. Proportionality of hazards was tested by assessing the significance of the addition of a time-dependent covariate consisting of the log of the follow-up time for the ECisF arm only. Median follow-up was calculated by the reverse Kaplan-Meier method. A P value of 5% was used for the primary end point, comparison of RFI between the two treatment groups. Elsewhere, a P value of 0.01 was used to define significance because of the large number of secondary end points examined. All P values are two-sided. The analysis was carried out on a database snapshot frozen in June 2009.
results
From May 1995 to January 2002, 349 patients were randomly assigned to receive ECisF (n = 172) or FEC60 (n = 177) (Figure 2) , indicating the true relative improvement with infusional ECisF is unlikely to be as large as the predicted 40%. A 40% reduction corresponded to the lower 95% CI for the observed HR, the true reduction is therefore unlikely to be less than this. This HR was changed only marginally on multivariate analysis to 0.81 (95% CI 0.57-1.14) when the effect of treatment was adjusted for nodal status, ER status and age. A total of 108 patients are recorded as having died, 60 allocated to FEC60 and 48 allocated to infusional ECisF, to give an overall survival HR of 0.78 (95% CI 0.53-1.13; P = 0.19) (Figure 3) . One patient died of breast cancer with date of relapse unknown but was considered to have relapsed at time of death. No deviation from proportional hazards was detected for either end point.
As expected, toxicity was noticeably higher with infusional ECisF than with FEC60 in TRAFIC (Table 3) . One in five patients treated with infusional ECisF experienced a severe Hickman line infection or had to have their Hickman line removed. Nausea and vomiting of grade 3 or 4 was higher with ECisF (21% versus 7%), diarrhoea and lethargy were also elevated. Grade 1 and 2 neuropathy was 30% and 16%, respectively, with 12% of patients in the infusional ECisF arm experiencing grade 3 or 4 PPE compared with 1% of FEC60 patients. Details of treatment delays and dose reductions are shown in Table 4 . discussion Six courses of adjuvant infusional ECisF was not shown to reduce the relapse rate in this trial when compared with equal duration FEC, despite the promising results observed in previous studies in patients with metastatic disease and as neoadjuvant treatment [3, 4] . In both these studies, chemotherapy was given for a slightly longer duration (eight courses) although this is unlikely to have been original article Annals of Oncology responsible for the difference in outcome. Results of the TRAFIC trial indicate that any benefit is unlikely to be as large as the 40% reduction in the relapse rate the trial was designed to detect, the observed reduction being 16% Figure 4 shows the chemotherapy effect on breast cancer mortality versus the effect on recurrence for the <50 and 50-69 age groups, divided by the three comparison types: CMF (combination chemotherapy with cyclophosphamide, methotrexate and 5-FU)-based polychemotherapy versus nil, anthracycline-based polychemotherapy versus nil and other polychemotherapy versus nil. The magnitude of the effect on mortality was on average 8% less than on recurrence (P = 0.007). The same comparison for anthracycline-versus nonanthracycline-containing polychemotherapy, which included 14 470 women, illustrates results observed when an effective agent is included in one polychemotherapy regimen of twoarm comparisons. In this case, the mortality effect is greater than the recurrence effect but not clearly larger (on average 6% more, P = 0.21). This relationship between the mortality and recurrence effects is significantly different from that shown in the chemotherapy versus nil comparisons (P = 0.01).
On the basis that TOPIC and TRAFIC compared different polychemotherapy regimens rather than polychemotherapy versus nil, the sizes of the effects on recurrence and survival are not therefore contradictory.
Since planning this trial, capecitabine, an oral fluoropyrimidine, has largely replaced infusional 5-FU in the treatment of advanced breast cancer [7, 8] and is now being tested in adjuvant and neoadjuvant regimens, sometimes but not always in combination with a taxane [9] [10] [11] [12] .
In conclusion, the TRAFIC and the TOPIC trials have not shown that the high efficacy of continuous infusional 5-FU with epirubicin and cisplatin in metastatic and locally advanced breast cancer can be translated into benefit in the treatment of early breast cancer. 
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